WO2003025568A3 - Identifizierung von antigenen durch xenogene, allogene oder autologe antikörper-vermittelte präzipitation - Google Patents

Identifizierung von antigenen durch xenogene, allogene oder autologe antikörper-vermittelte präzipitation Download PDF

Info

Publication number
WO2003025568A3
WO2003025568A3 PCT/EP2002/010318 EP0210318W WO03025568A3 WO 2003025568 A3 WO2003025568 A3 WO 2003025568A3 EP 0210318 W EP0210318 W EP 0210318W WO 03025568 A3 WO03025568 A3 WO 03025568A3
Authority
WO
WIPO (PCT)
Prior art keywords
allogenic
xenogenic
antigens
identification
autologous
Prior art date
Application number
PCT/EP2002/010318
Other languages
English (en)
French (fr)
Other versions
WO2003025568A9 (de
WO2003025568A2 (de
Inventor
Reinhard Zeidler
Original Assignee
Reinhard Zeidler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10151051A external-priority patent/DE10151051B4/de
Application filed by Reinhard Zeidler filed Critical Reinhard Zeidler
Priority to AU2002333840A priority Critical patent/AU2002333840A1/en
Priority to EP02798721A priority patent/EP1428028A2/de
Priority to US10/489,516 priority patent/US20050037437A1/en
Publication of WO2003025568A2 publication Critical patent/WO2003025568A2/de
Publication of WO2003025568A3 publication Critical patent/WO2003025568A3/de
Publication of WO2003025568A9 publication Critical patent/WO2003025568A9/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung beschreibt ein Verfahren zur Identifizierung von Antigenen, die mit Krankheiten assoziiert sind, bei denen es zur Ausbildung einer humoralen Immunantwort und damit zur Bildung spezifischer Antikörper kommt. Das Verfahren basiert auf der durch autologe, allogene oder xenogene Antikörper vermittelten Präzipitation von Antigenen aus Zelllysaten oder Bakterien-, Parasiten- und/oder Virenpräparaten mit autologen, allogenen und/oder xenogenen Seren, Aszites oder Pleuralflüssigkeiten.
PCT/EP2002/010318 2001-09-14 2002-09-13 Identifizierung von antigenen durch xenogene, allogene oder autologe antikörper-vermittelte präzipitation WO2003025568A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002333840A AU2002333840A1 (en) 2001-09-14 2002-09-13 Identification of antigens by xenogenic, allogenic or autologous antibody-mediated precipitation
EP02798721A EP1428028A2 (de) 2001-09-14 2002-09-13 Identifizierung von antigenen durch xenogene, allogene oder autologe antikörper-vermittelte präzipitation
US10/489,516 US20050037437A1 (en) 2001-09-14 2002-09-13 Identification of antigen by xenogenic, allogenic or autologous antibody-mediated precipitation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10145384 2001-09-14
DE10145384.1 2001-09-14
DE10151051.9 2001-10-16
DE10151051A DE10151051B4 (de) 2001-09-14 2001-10-16 Identifizierung von Antigenen durch xenogene, allogene oder autologe Antikörper-vermittelte Präzipitation

Publications (3)

Publication Number Publication Date
WO2003025568A2 WO2003025568A2 (de) 2003-03-27
WO2003025568A3 true WO2003025568A3 (de) 2003-09-12
WO2003025568A9 WO2003025568A9 (de) 2004-12-29

Family

ID=26010140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010318 WO2003025568A2 (de) 2001-09-14 2002-09-13 Identifizierung von antigenen durch xenogene, allogene oder autologe antikörper-vermittelte präzipitation

Country Status (3)

Country Link
US (1) US20050037437A1 (de)
EP (1) EP1428028A2 (de)
WO (1) WO2003025568A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003903317A0 (en) * 2003-06-27 2003-07-10 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
US8999652B2 (en) * 2007-08-10 2015-04-07 Primity Bio, Inc. Biological encoding of large numbers of cells
CN104634979A (zh) * 2013-11-15 2015-05-20 汕头大学 微生物细胞表面抗原的筛选与鉴定方法
PT3331818T (pt) * 2015-08-04 2024-08-30 Zoetis Services Llc Amplificação de sinal em ensaios de parceiro de ligação específica plasmónicos à base de solução
JP7308148B2 (ja) 2017-01-30 2023-07-13 ゾエティス サービシズ リミテッド ライアビリティ カンパニー 溶液ベースのプラズモン特異的結合パートナーアッセイおよび金属ナノ構造体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037777A1 (en) * 1995-05-23 1996-11-28 Nelson Randall W Mass spectrometric immunoassay
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
FR2808445A1 (fr) * 2000-05-04 2001-11-09 Pf Medicament Proteine omp associee a un lysat de cellules tumorales autologues et/ou heterologues

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
WO1996037777A1 (en) * 1995-05-23 1996-11-28 Nelson Randall W Mass spectrometric immunoassay
FR2808445A1 (fr) * 2000-05-04 2001-11-09 Pf Medicament Proteine omp associee a un lysat de cellules tumorales autologues et/ou heterologues

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 2000-245420, XP002234499, "Method for carrying out antigen immunoassay in biological fluids" *
OBATA Y ET AL: "SEREX ANALYSIS OF GASTRIC CANCER ANTIGENS", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 46, no. SUPPL, June 2000 (2000-06-01), pages S37 - S42, XP001057196, ISSN: 0344-5704 *

Also Published As

Publication number Publication date
WO2003025568A9 (de) 2004-12-29
WO2003025568A2 (de) 2003-03-27
EP1428028A2 (de) 2004-06-16
US20050037437A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
WO2004092209A3 (en) S. pneumoniae antigens
WO2004078907A3 (en) Streptococcus pyogenes antigens
WO2003011899A3 (en) Antigenic polypeptides
EP2289907A3 (de) Streptococcus agalactiae-Antigene I + II
EP1221342A3 (de) Verfahren zur Trennung von Zellen von einer Probe
WO2002090961A3 (en) Systems and methods for detection of analytes in biological fluids
NZ527440A (en) A method for indentification, isolation and production of antigens to a specific pathogen
WO2004025248A3 (en) Antibody pair screening methods
EP1916297A3 (de) Zelltrennungszusammensetzungen und -verfahren
WO2001071732A3 (de) Porous ferro- or ferrimagnetic glass particles for isolating molecules
WO2006040764A3 (en) System and method for production of antibodies in plant cell culture
EP1139101A3 (de) Immunoassay für C-reaktives Protein
AU2003900944A0 (en) Cell isolation & enrichment
WO2003092630A3 (en) Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
WO2003006154A3 (en) Protein design automation for designing protein libraries with altered immunogenicity
WO2008076255A3 (en) Canine thymic stromal lymphopoietin protein and uses thereof
WO2003025568A3 (de) Identifizierung von antigenen durch xenogene, allogene oder autologe antikörper-vermittelte präzipitation
WO2008089074A3 (en) Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
WO2000035950A3 (en) Reagents and methods useful for detecting diseases of the breast
WO2001066568A3 (en) Use of recombinant antigens to determine the immune status of an animal
WO2002048716A3 (en) Differential phage capture proteomics
EP0100955A3 (de) Monoklonale Immunoglobulin-M-Antikörper und Verfahren zu deren Herstellung
AU2003283240A1 (en) Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells
EP2182065A3 (de) Staphylococcus epidermidis Antigene
WO2002074904A3 (en) Rearranged squamous cell carcinoma antigen genes ii

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002798721

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002798721

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10489516

Country of ref document: US

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/13-13/13

WWW Wipo information: withdrawn in national office

Ref document number: 2002798721

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP